The N-end rule pathway is a conserved proteolytic system that governs protein turnover by recognising specific destabilising residues at the N-terminus of substrates – so‐called N‐degrons. This ...
This article is based on a poster originally authored by Mat Calder, Ben Durham, Amy Prosser, Miguel Coelho, Aimee Blair, Jack Cobb, Marta Falcicchio, Ruben Alvarez Fernandez, Emma Ford, Alberto ...
Targeted protein degradation tricks the internal machinery of cells in weeds to destroy proteins that are essential to their survival.
In the world of protein degradation, sometimes a spanner in the works isn’t an inconvenience but the desired result. Paris-based Enodia Therapeutics has launched out of France’s Pasteur Institute and ...
Grove Biopharma, a private biotechnology company engineering protein-like polymers (PLPs) -- a new class of multifunctional biologics designed to address the most challenging intracellular drug ...
Therapeutics that leverage protein degradation as their primary mechanism of action appear to be a validated new therapeutic modality. The current clinical molecules are focused on degrading ...
Undruggable targets typically refer to a class of therapeutic targets that are difficult to target through conventional methods or have not yet been targeted, but are of great clinical significance.
Autophagy and lysosomal pathways orchestrate unconventional secretion of Parkinson’s disease protein
Oxidative stress induced by 6-OHDA stimulates autophagy flux, which enhances STX17-mediated autolysosome formation, leading to the degradation of autophagosomal contents. However, in response to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results